|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:ACLY-AATF (FusionGDB2 ID:HG47TG26574) |
Fusion Gene Summary for ACLY-AATF |
Fusion gene summary |
Fusion gene information | Fusion gene name: ACLY-AATF | Fusion gene ID: hg47tg26574 | Hgene | Tgene | Gene symbol | ACLY | AATF | Gene ID | 47 | 26574 |
Gene name | ATP citrate lyase | apoptosis antagonizing transcription factor | |
Synonyms | ACL|ATPCL|CLATP | BFR2|CHE-1|CHE1|DED | |
Cytomap | ('ACLY')('AATF') 17q21.2 | 17q12 | |
Type of gene | protein-coding | protein-coding | |
Description | ATP-citrate synthaseATP-citrate (pro-S-)-lyasecitrate cleavage enzyme | protein AATFrb-binding protein Che-1 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | P53396 | . | |
Ensembl transtripts involved in fusion gene | ENST00000352035, ENST00000353196, ENST00000393896, ENST00000537919, ENST00000590151, ENST00000588779, | ||
Fusion gene scores | * DoF score | 11 X 14 X 6=924 | 26 X 13 X 11=3718 |
# samples | 13 | 28 | |
** MAII score | log2(13/924*10)=-2.8293812283876 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(28/3718*10)=-3.73102803797452 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ACLY [Title/Abstract] AND AATF [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | ACLY(40054002)-AATF(35343916), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | ACLY-AATF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACLY-AATF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACLY-AATF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ACLY-AATF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ACLY-AATF seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ACLY | GO:0006085 | acetyl-CoA biosynthetic process | 1371749 |
Hgene | ACLY | GO:0006101 | citrate metabolic process | 1371749 |
Hgene | ACLY | GO:0006107 | oxaloacetate metabolic process | 1371749 |
Hgene | ACLY | GO:0008610 | lipid biosynthetic process | 23932781 |
Tgene | AATF | GO:0032929 | negative regulation of superoxide anion generation | 15207272 |
Tgene | AATF | GO:0045944 | positive regulation of transcription by RNA polymerase II | 18049476 |
Tgene | AATF | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 15207272 |
Fusion gene breakpoints across ACLY (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across AATF (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | BRCA | TCGA-AC-A3W5-01A | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
Top |
Fusion Gene ORF analysis for ACLY-AATF |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-intron | ENST00000352035 | ENST00000590321 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
5CDS-intron | ENST00000353196 | ENST00000590321 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
5CDS-intron | ENST00000393896 | ENST00000590321 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
5CDS-intron | ENST00000537919 | ENST00000590321 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
5CDS-intron | ENST00000590151 | ENST00000590321 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
Frame-shift | ENST00000393896 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
Frame-shift | ENST00000590151 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
In-frame | ENST00000352035 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
In-frame | ENST00000353196 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
In-frame | ENST00000537919 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
intron-3CDS | ENST00000588779 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
intron-intron | ENST00000588779 | ENST00000590321 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000352035 | ACLY | chr17 | 40054002 | - | ENST00000225402 | AATF | chr17 | 35343916 | + | 2618 | 1560 | 131 | 2410 | 759 |
ENST00000353196 | ACLY | chr17 | 40054002 | - | ENST00000225402 | AATF | chr17 | 35343916 | + | 2650 | 1592 | 163 | 2442 | 759 |
ENST00000537919 | ACLY | chr17 | 40054002 | - | ENST00000225402 | AATF | chr17 | 35343916 | + | 1831 | 773 | 127 | 1623 | 498 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000352035 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + | 0.004321913 | 0.9956781 |
ENST00000353196 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + | 0.004237543 | 0.9957625 |
ENST00000537919 | ENST00000225402 | ACLY | chr17 | 40054002 | - | AATF | chr17 | 35343916 | + | 0.004935449 | 0.99506456 |
Top |
Fusion Genomic Features for ACLY-AATF |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
ACLY | chr17 | 40054001 | - | AATF | chr17 | 35343915 | + | 1.57E-09 | 1 |
ACLY | chr17 | 40054001 | - | AATF | chr17 | 35343915 | + | 1.57E-09 | 1 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ACLY-AATF |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:40054002/chr17:35343916) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ACLY | . |
FUNCTION: Catalyzes the cleavage of citrate into oxaloacetate and acetyl-CoA, the latter serving as common substrate for de novo cholesterol and fatty acid synthesis. {ECO:0000269|PubMed:10653665, ECO:0000269|PubMed:1371749, ECO:0000269|PubMed:19286649, ECO:0000269|PubMed:23932781, ECO:0000269|PubMed:9116495}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000352035 | - | 13 | 29 | 4_265 | 476 | 1102.0 | Domain | Note=ATP-grasp |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000353196 | - | 13 | 28 | 4_265 | 476 | 1092.0 | Domain | Note=ATP-grasp |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000393896 | - | 13 | 28 | 4_265 | 476 | 1092.0 | Domain | Note=ATP-grasp |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000590151 | - | 13 | 29 | 4_265 | 476 | 1102.0 | Domain | Note=ATP-grasp |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000352035 | - | 13 | 29 | 109_111 | 476 | 1102.0 | Nucleotide binding | Note=ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000352035 | - | 13 | 29 | 66_67 | 476 | 1102.0 | Nucleotide binding | Note=ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000353196 | - | 13 | 28 | 109_111 | 476 | 1092.0 | Nucleotide binding | Note=ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000353196 | - | 13 | 28 | 66_67 | 476 | 1092.0 | Nucleotide binding | Note=ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000393896 | - | 13 | 28 | 109_111 | 476 | 1092.0 | Nucleotide binding | Note=ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000393896 | - | 13 | 28 | 66_67 | 476 | 1092.0 | Nucleotide binding | Note=ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000590151 | - | 13 | 29 | 109_111 | 476 | 1102.0 | Nucleotide binding | Note=ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000590151 | - | 13 | 29 | 66_67 | 476 | 1102.0 | Nucleotide binding | Note=ATP |
Tgene | AATF | chr17:40054002 | chr17:35343916 | ENST00000225402 | 3 | 12 | 316_372 | 277 | 561.0 | Region | Note=RB1 binding | |
Tgene | AATF | chr17:40054002 | chr17:35343916 | ENST00000225402 | 3 | 12 | 373_472 | 277 | 561.0 | Region | Note=RB1 and SP1 binding |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000352035 | - | 13 | 29 | 701_721 | 476 | 1102.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000352035 | - | 13 | 29 | 752_778 | 476 | 1102.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000353196 | - | 13 | 28 | 701_721 | 476 | 1092.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000353196 | - | 13 | 28 | 752_778 | 476 | 1092.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000393896 | - | 13 | 28 | 701_721 | 476 | 1092.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000393896 | - | 13 | 28 | 752_778 | 476 | 1092.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000590151 | - | 13 | 29 | 701_721 | 476 | 1102.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000590151 | - | 13 | 29 | 752_778 | 476 | 1102.0 | Nucleotide binding | ATP |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000352035 | - | 13 | 29 | 779_789 | 476 | 1102.0 | Region | CoA-binding |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000353196 | - | 13 | 28 | 779_789 | 476 | 1092.0 | Region | CoA-binding |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000393896 | - | 13 | 28 | 779_789 | 476 | 1092.0 | Region | CoA-binding |
Hgene | ACLY | chr17:40054002 | chr17:35343916 | ENST00000590151 | - | 13 | 29 | 779_789 | 476 | 1102.0 | Region | CoA-binding |
Tgene | AATF | chr17:40054002 | chr17:35343916 | ENST00000225402 | 3 | 12 | 96_195 | 277 | 561.0 | Compositional bias | Note=Glu-rich | |
Tgene | AATF | chr17:40054002 | chr17:35343916 | ENST00000225402 | 3 | 12 | 273_315 | 277 | 561.0 | Region | Note=POLR2J binding |
Top |
Fusion Gene Sequence for ACLY-AATF |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>1324_1324_1_ACLY-AATF_ACLY_chr17_40054002_ENST00000352035_AATF_chr17_35343916_ENST00000225402_length(transcript)=2618nt_BP=1560nt CCGGGACAAAAGCCGGATCCCGGGAAGCTACCGGCTGCTGGGGTGCTCCGGATTTTGCGGGGTTCGTCGGGCCTGTGGAAGAAGCGCCGC GCACGGACTTCGGCAGAGGTAGAGCAGGTCTCTCTGCAGCCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTTTACA AGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCACTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACC ACCCCTGGCTGCTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGGGTCAACCTCA CTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAGCCACAGTTGGCAAGGCCACAGGCTTCCTCAAGAACTTTCTGA TCGAGCCCTTCGTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCACCCGAGAAGGGGACTACGTCCTGTTCCACCACG AGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGAAGCTGCTTGTTGGCGTGGATGAGAAACTGAATCCTGAGGACATCAAAA AACACCTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTCCGGCCTCTTCAATTTCTACGAGGACTTGTACT TCACCTACCTCGAGATCAATCCCCTTGTAGTGACCAAAGATGGAGTCTATGTCCTTGACTTGGCGGCCAAGGTGGACGCCACTGCCGACT ACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGCATATCCAGAGGAAGCCTACATTGCAGACCTCG ATGCCAAAAGTGGGGCAAGCCTGAAGCTGACCTTGCTGAACCCCAAAGGGAGGATCTGGACCATGGTGGCCGGGGGTGGCGCCTCTGTCG TGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGGGAGTACTCAGGCGCCCCCAGCGAGCAGCAGACCT ATGACTATGCCAAGACTATCCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAAGATCCTCATCATTGGAGGCAGCATCGCAAACT TCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGATTACCAGGGCCCCCTGAAGGAGCACGAAGTCACAATCTTTG TCCGAAGAGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGGGATCCCCATCCATGTCTTTGGCA CAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCACCGGCCCATCCCCAACCAGCCACCCACAGCGGCCCACACTGCAAACT TCCTCCTCAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTCCAGGGCCGATGAGGTGGCGCCTG CAAAGAAGGCCAAGCCTGCCATGCCACAAGGTCACAAGGCACTTAAAGCATTGTTGAGGTCATTGGTAGGTCTTCAGGAAGAGTTGCTTT TCCAGTACCCAGACACTAGATATCTAGTAGATGGGACAAAGCCCAATGCGGGAAGTGAGGAGATTTCTAGTGAAGATGATGAGCTGGTAG AAGAGAAGAAGCAGCAACGAAGAAGGGTCCCTGCAAAGAGGAAGCTGGAGATGGAGGACTATCCCAGCTTCATGGCAAAGCGCTTTGCCG ACTTTACAGTCTACAGGAACCGCACACTTCAGAAATGGCACGATAAGACCAAACTGGCTTCTGGAAAACTGGGGAAGGGTTTTGGTGCCT TTGAACGCTCAATCTTGACTCAGATCGACCATATTCTGATGGACAAAGAGAGATTACTTCGAAGGACACAGACCAAGCGCTCTGTCTATC GAGTTCTTGGCAAACCTGAGCCAGCAGCTCAGCCTGTCCCAGAGAGTTTGCCAGGGGAACCGGAGATCCTTCCTCAAGCCCCTGCTAATG CTCATCTGAAGGACTTGGATGAAGAAATCTTTGATGATGATGACTTTTACCACCAGCTCCTTCGAGAACTCATAGAACGGAAGACCAGCT CCTTGGATCCCAACGATCAGGTGGCCATGGGAAGGCAGTGGCTTGCAATCCAGAAGTTACGAAGCAAAATCCACAAAAAAGTAGATAGGA AAGCCAGCAAAGGCAGGAAACTTCGGTTTCATGTCCTTAGCAAGCTACTGAGTTTCATGGCACCTATTGACCATACTACAATGAATGATG ATGCCAGGACAGAACTGTACCGCTCTCTTTTTGGCCAGCTCCACCCTCCCGACGAAGGCCACGGGGATTGACATCGCCCACCTCCGACAC CCAGTGGGCGCCTTGGCTGGTGCGGCTGCTGGTCCAGATGGAGGAAACCAGTGACTTTATGGGGCTGAGCTAGTAGGGAAGCCCCTGGAA AGATGCTGCGTTCCGAACCTGTGCCTAATACACGCAAGGGCGCTGTCCCGCCCAACCCCGCCTTTAAACGCCACAAATAAAGAGCATTGT >1324_1324_1_ACLY-AATF_ACLY_chr17_40054002_ENST00000352035_AATF_chr17_35343916_ENST00000225402_length(amino acids)=759AA_BP=476 MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLG QEATVGKATGFLKNFLIEPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAPEDKKEI LASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLN PKGRIWTMVAGGGASVVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANFTNVAATFKGIVRA IRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAP SRTASFSESRADEVAPAKKAKPAMPQGHKALKALLRSLVGLQEELLFQYPDTRYLVDGTKPNAGSEEISSEDDELVEEKKQQRRRVPAKR KLEMEDYPSFMAKRFADFTVYRNRTLQKWHDKTKLASGKLGKGFGAFERSILTQIDHILMDKERLLRRTQTKRSVYRVLGKPEPAAQPVP ESLPGEPEILPQAPANAHLKDLDEEIFDDDDFYHQLLRELIERKTSSLDPNDQVAMGRQWLAIQKLRSKIHKKVDRKASKGRKLRFHVLS -------------------------------------------------------------- >1324_1324_2_ACLY-AATF_ACLY_chr17_40054002_ENST00000353196_AATF_chr17_35343916_ENST00000225402_length(transcript)=2650nt_BP=1592nt AGCCGATGGGGGCGGGGAAAAGTCCGGCTGGGCCGGGACAAAAGCCGGATCCCGGGAAGCTACCGGCTGCTGGGGTGCTCCGGATTTTGC GGGGTTCGTCGGGCCTGTGGAAGAAGCGCCGCGCACGGACTTCGGCAGAGGTAGAGCAGGTCTCTCTGCAGCCATGTCGGCCAAGGCAAT TTCAGAGCAGACGGGCAAAGAACTCCTTTACAAGTTCATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCACTCC TGACACAGACTGGGCCCGCTTGCTGCAGGACCACCCCTGGCTGCTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCG TGGAAAACTTGGTCTCGTTGGGGTCAACCTCACTCTGGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAGCCACAGTTGG CAAGGCCACAGGCTTCCTCAAGAACTTTCTGATCGAGCCCTTCGTCCCCCACAGTCAGGCTGAGGAGTTCTATGTCTGCATCTATGCCAC CCGAGAAGGGGACTACGTCCTGTTCCACCACGAGGGGGGTGTGGACGTGGGTGATGTGGACGCCAAGGCCCAGAAGCTGCTTGTTGGCGT GGATGAGAAACTGAATCCTGAGGACATCAAAAAACACCTGTTGGTCCACGCCCCTGAAGACAAGAAAGAAATTCTGGCCAGTTTTATCTC CGGCCTCTTCAATTTCTACGAGGACTTGTACTTCACCTACCTCGAGATCAATCCCCTTGTAGTGACCAAAGATGGAGTCTATGTCCTTGA CTTGGCGGCCAAGGTGGACGCCACTGCCGACTACATCTGCAAAGTGAAGTGGGGTGACATCGAGTTCCCTCCCCCCTTCGGGCGGGAGGC ATATCCAGAGGAAGCCTACATTGCAGACCTCGATGCCAAAAGTGGGGCAAGCCTGAAGCTGACCTTGCTGAACCCCAAAGGGAGGATCTG GACCATGGTGGCCGGGGGTGGCGCCTCTGTCGTGTACAGCGATACCATCTGTGATCTAGGGGGTGTCAACGAGCTGGCAAACTATGGGGA GTACTCAGGCGCCCCCAGCGAGCAGCAGACCTATGACTATGCCAAGACTATCCTCTCCCTCATGACCCGAGAGAAGCACCCAGATGGCAA GATCCTCATCATTGGAGGCAGCATCGCAAACTTCACCAACGTGGCTGCCACGTTCAAGGGCATCGTGAGAGCAATTCGAGATTACCAGGG CCCCCTGAAGGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAA GACCACTGGGATCCCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCACCGGCCCATCCCCAA CCAGCCACCCACAGCGGCCCACACTGCAAACTTCCTCCTCAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTT TTCTGAGTCCAGGGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGTCACAAGGCACTTAAAGCATTGTTGAG GTCATTGGTAGGTCTTCAGGAAGAGTTGCTTTTCCAGTACCCAGACACTAGATATCTAGTAGATGGGACAAAGCCCAATGCGGGAAGTGA GGAGATTTCTAGTGAAGATGATGAGCTGGTAGAAGAGAAGAAGCAGCAACGAAGAAGGGTCCCTGCAAAGAGGAAGCTGGAGATGGAGGA CTATCCCAGCTTCATGGCAAAGCGCTTTGCCGACTTTACAGTCTACAGGAACCGCACACTTCAGAAATGGCACGATAAGACCAAACTGGC TTCTGGAAAACTGGGGAAGGGTTTTGGTGCCTTTGAACGCTCAATCTTGACTCAGATCGACCATATTCTGATGGACAAAGAGAGATTACT TCGAAGGACACAGACCAAGCGCTCTGTCTATCGAGTTCTTGGCAAACCTGAGCCAGCAGCTCAGCCTGTCCCAGAGAGTTTGCCAGGGGA ACCGGAGATCCTTCCTCAAGCCCCTGCTAATGCTCATCTGAAGGACTTGGATGAAGAAATCTTTGATGATGATGACTTTTACCACCAGCT CCTTCGAGAACTCATAGAACGGAAGACCAGCTCCTTGGATCCCAACGATCAGGTGGCCATGGGAAGGCAGTGGCTTGCAATCCAGAAGTT ACGAAGCAAAATCCACAAAAAAGTAGATAGGAAAGCCAGCAAAGGCAGGAAACTTCGGTTTCATGTCCTTAGCAAGCTACTGAGTTTCAT GGCACCTATTGACCATACTACAATGAATGATGATGCCAGGACAGAACTGTACCGCTCTCTTTTTGGCCAGCTCCACCCTCCCGACGAAGG CCACGGGGATTGACATCGCCCACCTCCGACACCCAGTGGGCGCCTTGGCTGGTGCGGCTGCTGGTCCAGATGGAGGAAACCAGTGACTTT ATGGGGCTGAGCTAGTAGGGAAGCCCCTGGAAAGATGCTGCGTTCCGAACCTGTGCCTAATACACGCAAGGGCGCTGTCCCGCCCAACCC >1324_1324_2_ACLY-AATF_ACLY_chr17_40054002_ENST00000353196_AATF_chr17_35343916_ENST00000225402_length(amino acids)=759AA_BP=476 MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLG QEATVGKATGFLKNFLIEPFVPHSQAEEFYVCIYATREGDYVLFHHEGGVDVGDVDAKAQKLLVGVDEKLNPEDIKKHLLVHAPEDKKEI LASFISGLFNFYEDLYFTYLEINPLVVTKDGVYVLDLAAKVDATADYICKVKWGDIEFPPPFGREAYPEEAYIADLDAKSGASLKLTLLN PKGRIWTMVAGGGASVVYSDTICDLGGVNELANYGEYSGAPSEQQTYDYAKTILSLMTREKHPDGKILIIGGSIANFTNVAATFKGIVRA IRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNASGSTSTPAP SRTASFSESRADEVAPAKKAKPAMPQGHKALKALLRSLVGLQEELLFQYPDTRYLVDGTKPNAGSEEISSEDDELVEEKKQQRRRVPAKR KLEMEDYPSFMAKRFADFTVYRNRTLQKWHDKTKLASGKLGKGFGAFERSILTQIDHILMDKERLLRRTQTKRSVYRVLGKPEPAAQPVP ESLPGEPEILPQAPANAHLKDLDEEIFDDDDFYHQLLRELIERKTSSLDPNDQVAMGRQWLAIQKLRSKIHKKVDRKASKGRKLRFHVLS -------------------------------------------------------------- >1324_1324_3_ACLY-AATF_ACLY_chr17_40054002_ENST00000537919_AATF_chr17_35343916_ENST00000225402_length(transcript)=1831nt_BP=773nt GACAAAAGCCGGATCCCGGGAAGCTACCGGCTGCTGGGGTGCTCCGGATTTTGCGGGGTTCGTCGGGCCTGTGGAAGAAGCGCCGCGCAC GGACTTCGGCAGAGGTAGAGCAGGTCTCTCTGCAGCCATGTCGGCCAAGGCAATTTCAGAGCAGACGGGCAAAGAACTCCTTTACAAGTT CATCTGTACCACCTCAGCCATCCAGAATCGGTTCAAGTATGCTCGGGTCACTCCTGACACAGACTGGGCCCGCTTGCTGCAGGACCACCC CTGGCTGCTCAGCCAGAACTTGGTAGTCAAGCCAGACCAGCTGATCAAACGTCGTGGAAAACTTGGTCTCGTTGGGGTCAACCTCACTCT GGATGGGGTCAAGTCCTGGCTGAAGCCACGGCTGGGACAGGAAGCCACAGGCATCGTGAGAGCAATTCGAGATTACCAGGGCCCCCTGAA GGAGCACGAAGTCACAATCTTTGTCCGAAGAGGTGGCCCCAACTATCAGGAGGGCTTACGGGTGATGGGAGAAGTCGGGAAGACCACTGG GATCCCCATCCATGTCTTTGGCACAGAGACTCACATGACGGCCATTGTGGGCATGGCCCTGGGCCACCGGCCCATCCCCAACCAGCCACC CACAGCGGCCCACACTGCAAACTTCCTCCTCAACGCCAGCGGGAGCACATCGACGCCAGCCCCCAGCAGGACAGCATCTTTTTCTGAGTC CAGGGCCGATGAGGTGGCGCCTGCAAAGAAGGCCAAGCCTGCCATGCCACAAGGTCACAAGGCACTTAAAGCATTGTTGAGGTCATTGGT AGGTCTTCAGGAAGAGTTGCTTTTCCAGTACCCAGACACTAGATATCTAGTAGATGGGACAAAGCCCAATGCGGGAAGTGAGGAGATTTC TAGTGAAGATGATGAGCTGGTAGAAGAGAAGAAGCAGCAACGAAGAAGGGTCCCTGCAAAGAGGAAGCTGGAGATGGAGGACTATCCCAG CTTCATGGCAAAGCGCTTTGCCGACTTTACAGTCTACAGGAACCGCACACTTCAGAAATGGCACGATAAGACCAAACTGGCTTCTGGAAA ACTGGGGAAGGGTTTTGGTGCCTTTGAACGCTCAATCTTGACTCAGATCGACCATATTCTGATGGACAAAGAGAGATTACTTCGAAGGAC ACAGACCAAGCGCTCTGTCTATCGAGTTCTTGGCAAACCTGAGCCAGCAGCTCAGCCTGTCCCAGAGAGTTTGCCAGGGGAACCGGAGAT CCTTCCTCAAGCCCCTGCTAATGCTCATCTGAAGGACTTGGATGAAGAAATCTTTGATGATGATGACTTTTACCACCAGCTCCTTCGAGA ACTCATAGAACGGAAGACCAGCTCCTTGGATCCCAACGATCAGGTGGCCATGGGAAGGCAGTGGCTTGCAATCCAGAAGTTACGAAGCAA AATCCACAAAAAAGTAGATAGGAAAGCCAGCAAAGGCAGGAAACTTCGGTTTCATGTCCTTAGCAAGCTACTGAGTTTCATGGCACCTAT TGACCATACTACAATGAATGATGATGCCAGGACAGAACTGTACCGCTCTCTTTTTGGCCAGCTCCACCCTCCCGACGAAGGCCACGGGGA TTGACATCGCCCACCTCCGACACCCAGTGGGCGCCTTGGCTGGTGCGGCTGCTGGTCCAGATGGAGGAAACCAGTGACTTTATGGGGCTG AGCTAGTAGGGAAGCCCCTGGAAAGATGCTGCGTTCCGAACCTGTGCCTAATACACGCAAGGGCGCTGTCCCGCCCAACCCCGCCTTTAA >1324_1324_3_ACLY-AATF_ACLY_chr17_40054002_ENST00000537919_AATF_chr17_35343916_ENST00000225402_length(amino acids)=498AA_BP=215 MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWLLSQNLVVKPDQLIKRRGKLGLVGVNLTLDGVKSWLKPRLG QEATGIVRAIRDYQGPLKEHEVTIFVRRGGPNYQEGLRVMGEVGKTTGIPIHVFGTETHMTAIVGMALGHRPIPNQPPTAAHTANFLLNA SGSTSTPAPSRTASFSESRADEVAPAKKAKPAMPQGHKALKALLRSLVGLQEELLFQYPDTRYLVDGTKPNAGSEEISSEDDELVEEKKQ QRRRVPAKRKLEMEDYPSFMAKRFADFTVYRNRTLQKWHDKTKLASGKLGKGFGAFERSILTQIDHILMDKERLLRRTQTKRSVYRVLGK PEPAAQPVPESLPGEPEILPQAPANAHLKDLDEEIFDDDDFYHQLLRELIERKTSSLDPNDQVAMGRQWLAIQKLRSKIHKKVDRKASKG -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ACLY-AATF |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ACLY-AATF |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | ACLY | P53396 | DB11936 | Bempedoic acid | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for ACLY-AATF |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | ACLY | C0018801 | Heart failure | 1 | CTD_human |
Hgene | ACLY | C0018802 | Congestive heart failure | 1 | CTD_human |
Hgene | ACLY | C0023212 | Left-Sided Heart Failure | 1 | CTD_human |
Hgene | ACLY | C0028754 | Obesity | 1 | CTD_human |
Hgene | ACLY | C0235527 | Heart Failure, Right-Sided | 1 | CTD_human |
Hgene | ACLY | C1959583 | Myocardial Failure | 1 | CTD_human |
Hgene | ACLY | C1961112 | Heart Decompensation | 1 | CTD_human |
Hgene | ACLY | C2239176 | Liver carcinoma | 1 | CTD_human |